On 5 February 2026, CVS Health announced that pharmacy benefits manager, CVS Caremark, will begin offering Samsung Bioepis’ Ospomyv® and Celltrion’s Stoboclo®, biosimilars to Amgen’s Prolia® (denosumab), on major US national commercial template formularies from 1 April 2026.
According to CVS, this is aimed at helping to expand the adoption of lower-cost biosimilar medications, and builds on its exclusion of AbbVie’s Humira® (adalimumab) from its formulary in favour of adalimumab biosimilars priced at a discount, including Sandoz’s Hyrimoz®.
Samsung Bioepis’ Ospomyv® was the second Prolia® biosimilar approved in the US (in February 2025). BPCIA litigation commenced by Amgen alleging that Samsung Bioepis’ denosumab biosimilars infringed 36 US patents relating to denosumab was settled in September 2025.
Amgen and Celltrion settled their BPCIA litigation regarding denosumab in January 2025, with Celltrion launching Stoboclo® in July 2025 (following FDA approval in March 2025). Celltrion’s second denosumab biosimilar, Osenvelt®, biosimilar to Amgen’s Xgeva®, was previously included on the CVS Caremark formulary.